Literature DB >> 10586188

Toxicity profile of interferon alfa-2b in children: A prospective evaluation.

J Dubois1, L Hershon, L Carmant, S Bélanger, J M Leclerc, M David.   

Abstract

The toxicity of interferon (IFN) alfa-2b therapy was prospectively evaluated in 53 children treated from 1991 to 1996 in 2 successive studies of IFN alfa therapy for severe hemangiomas at Sainte-Justine Hospital. Toxicity was generally mild and transient, with grade 1 toxicity occurring in 100% of patients, grade 2 toxicity in 89%, grade 3 toxicity in 58%, and grade 4 toxicity in 17%. Ten of 43 patients available for evaluation had an abnormal neurologic examination. Severe neurotoxicity in the form of spastic diplegia occurred in one patient. In conclusion, IFN alfa therapy is generally well tolerated in children. However, it may rarely be associated with severe toxicity and must be used with caution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586188     DOI: 10.1016/s0022-3476(99)70104-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Intralesional administration of interferon A for the management of severe haemangiomas.

Authors:  C Kaselas; G Tsikopoulos; G Papouis; V Kaselas
Journal:  Pediatr Surg Int       Date:  2006-12-15       Impact factor: 1.827

Review 2.  Pediatric gastrointestinal vascular anomalies: imaging and therapeutic issues.

Authors:  Josée Dubois; Françoise Rypens; Laurent Garel; Salam Yazbeck; Eric Therasse; Gilles Soulez
Journal:  Pediatr Radiol       Date:  2007-04-17

Review 3.  Management of infantile hemangiomas : current and potential pharmacotherapeutic approaches.

Authors:  Brittany G Craiglow; Richard J Antaya
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

4.  Kasabach merritt syndrome: management with interferon.

Authors:  Sandhya Acharya; Kalyani Pillai; Abel Francis; S Criton; V K Parvathi
Journal:  Indian J Dermatol       Date:  2010 Jul-Sep       Impact factor: 1.494

5.  Oral propranolol for the treatment of periorbital infantile hemangioma: a preliminary report from oman.

Authors:  Beena Harikrishna; Anuradha Ganesh; Sana Al-Zuahibi; Samia Al-Jabri; Ahmed Al-Waily; Adil Al-Riyami; Faisal Al-Azri; Feraz Masoud; Abdullah Al-Mujaini
Journal:  Middle East Afr J Ophthalmol       Date:  2011-10

6.  Clinical analysis of Kasabach-Merritt syndrome in 17 neonates.

Authors:  Ping Wang; Wei Zhou; Li Tao; Ning Zhao; Xiao-Wen Chen
Journal:  BMC Pediatr       Date:  2014-06-11       Impact factor: 2.125

7.  Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience.

Authors:  Hai Wei Wu; Xuan Wang; Ling Zhang; Hai Guang Zhao; Yan An Wang; Li Xin Su; Xin Dong Fan; Jia Wei Zheng
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

Review 8.  Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.

Authors:  Diego R Hijano; Luan D Vu; Lawrence M Kauvar; Ralph A Tripp; Fernando P Polack; Stephania A Cormier
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

Review 9.  Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections.

Authors:  Patricio L Acosta; Alana B Byrne; Diego R Hijano; Laura B Talarico
Journal:  J Immunol Res       Date:  2020-05-08       Impact factor: 4.818

Review 10.  Pathogenesis of hepatitis C during pregnancy and childhood.

Authors:  Armelle Le Campion; Ariane Larouche; Sébastien Fauteux-Daniel; Hugo Soudeyns
Journal:  Viruses       Date:  2012-12-06       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.